Lyra Therapeutics (LYRA) Misses Q1 EPS by 9c

Lyra Therapeutics (NASDAQ: LYRA) reported Q1 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $530 thousand versus the consensus estimate of $345.75 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Pinduoduo (PDD) Tops Q2 EPS by 98c
• X Financial (XYF) Tops Q2 EPS by 438c